Search

Your search keyword '"Horgan, Kieran"' showing total 476 results
Start Over Author "Horgan, Kieran"
476 results on '"Horgan, Kieran"'

3. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Published
2023
Full Text
View/download PDF

4. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Author

Dave, Rajiv V., Elsberger, Beatrix, Taxiarchi, Vicky P., Gandhi, Ashu, Kirwan, Cliona C., Kim, Baek, Camacho, Elizabeth M., Coles, Charlotte E., Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie J., Leff, Daniel R., McIntosh, Stuart A., O’Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, and Cutress, Ramsey I.

Published
2023
Full Text
View/download PDF

10. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

Author

Evans, Abigail, Ball, Adrian, Johri, Akhil, Nejim, Ali, Jones, Alison, Corder, Allan, Thorne, Amanda, Anand, Ambika, Chakrabarti, Amitabha, Robinson, Anne, Skene, Anthony, Modi, Anupam, Patel, Ashraf, Kothari, Ashutosh, McFall, Brendan, Mortimer, Caroline, Lee, Caroline, Chan, Charlie, Abson, Charlotte, Holcombe, Christopher, Hinton, Christopher, Hollywood, Ciaran, Murphy, Claire, Crowley, Clare, Harding-Mackean, Claudia, Griffith, Clive, Lewanski, Conrad, Rea, Daniel, Hwang, David, Crawford, Derek, Thekkinkattil, Dinesh, Ferguson, Douglas, Adamson, Douglas, Wheatley, Duncan, Ravichandran, Duraisamy, Babu, Ed, Hyett, Elaine, Ashkanani, Fawzia, Hoar, Fiona, Kenny, Frances, Dyke, Gary, Sparrow, Geoffrey, Gilbert, Cunnick, Giles, Algurafi, Hafiz, Sweetland, Helen, Prof, Highes-Davies, Hamed, Hisham, Smith, Ian, Laidlaw, Ian, Khattak, Ilyas, Newby, Jacqueline, Rees-Lee, Jacqueline, Kokan, Jalal, Barrett, Jane, Naik, Jay Dolatrai, Vaidya, Jayant, Forrest, Jennifer, Parmar, Jitendra, Adams, Jocelyn, Fox, John, Roberts, Jonathan, Dawson, Jonathan, Doughty, Julie, Donnelly, Jull, Dunn, Kathleen, Chin, Kian, Horgan, Kieran, Thakur, Kislaya, Barthelmes, Ludger, Wyld, Lynda, Bhattacharyya, Madhumita, Hadaki, Maher, Kishore, Makam, Ornstein, Marcus, Bramley, Maria, Bews-Hair, Maria, Parton, Marina, Sibbering, Mark, Kissin, Mark, Churn, Mark, Hogg, Martin, Quigley, Mary, Hatton, Matthew, Winter, Matthew, Adelekan, Matthew, Shere, Michael, Carr, Michael, Williams, Michael, Absar, Mohammed, Sharif, Muhammad, Kelleher, Muireann, Walji, Nawaz, Williams, Nicholas, Gallegos, Nicholas, Bundred, Nigel, Hatcher, Olivia, Crellin, Perric, Crane, Peter, Donnelly, Peter, Kneeshaw, Peter, Walker, Philip, Sinha, Prakash, Bhaskar, Pudhupalayam, Soulsby, Racheal, Todd, Radha, Vidya, Raghavan, Mehra, Rakesh, Prasad, Ramachandran, Cutress, Ramsay, Sharma, Ravi, Roylance, Rebecca, Goranova, Rebecca, Salman, Reem Ramzi, Bonom, Riccardo, Johnson, Richard, Sutton, Richard, Linforth, Rick, Coleman, Rob, Grieve, Robert, Leonard, Robert, Reichert, Robert, Kennedy, Robert, Agarwal, Roshan, Allerton, Rozenn, Burcombe, Russell, Davis, Ruth, Narayanan, Sankaran, Chandrasekharan, Sankaran, Vesty, Sarah, Seetharam, Seema, Ledwidge, Serena, Iqbal, Shabana, Wahee, Shamaela, Silva, Shobha, Pain, Simon, Holt, Simon, Thomson, Simon, Smith, Simon, Ellenbogen, Simon, Laws, Siobhan, Chan, Stephen, Johnston, Stephen, Holt, Steve, Thrush, Steven, McIntosh, Stuart, Chatterjee, Sumohan, Cleator, Susan, Usman, Tamoor, Johnson, Tayo, Kovacs, Tibor, Irvine, Tracey, Barthkur, Urmila, Pope, Vanessa, Brown, Victoria Alexandra, Muralikrishna, Vummiti, Samra, Walid, Maxwell, William, Winters, Zoe, Bergamino, Milana A., López-Knowles, Elena, Morani, Gabriele, Tovey, Holly, Kilburn, Lucy, Schuster, Eugene F., Alataki, Anastasia, Hills, Margaret, Xiao, Hui, Holcombe, Chris, Robertson, John F., Smith, Ian E., Bliss, Judith M., Dowsett, Mitch, and Cheang, Maggie C.U.

Published
2022
Full Text
View/download PDF

11. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National practice questionnaire of United Kingdom multi-disciplinary decision making

Author

Morgan, Jenna L., Cheng, Vinton, Barry, Peter A., Copson, Ellen, Cutress, Ramsey I., Dave, Rajiv, Elsberger, Beatrix, Fairbrother, Patricia, Hartup, Sue, Hogan, Brian, Horgan, Kieran, Kirwan, Cliona C., McIntosh, Stuart A., O'Connell, Rachel L., Patani, Neill, Potter, Shelley, Rattay, Tim, Sheehan, Lisa, Wyld, Lynda, and Kim, Baek

Published
2022
Full Text
View/download PDF

12. Survival outcomes after breast cancer surgery among older women with early invasive breast cancer in England: population-based cohort study.

Author

Miller, Katie, Gannon, Melissa Ruth, Medina, Jibby, Clements, Karen, Dodwell, David, Horgan, Kieran, Park, Min Hae, and Cromwell, David Alan

Subjects
BREAST cancer surgery, BREAST surgery, BREAST cancer, AGE differences, SURVIVAL rate
Abstract

Background This study assessed the influence of age, co-morbidity and frailty on 5-year survival outcomes after breast conservation surgery (BCS) with radiotherapy (RT) versus mastectomy (with or without RT) in women with early invasive breast cancer. Methods Women aged over 50 years with early invasive breast cancer diagnosed in England (2014–2019) who had breast surgery were identified from Cancer Registry data. Survival estimates were calculated from a flexible parametric survival model. A competing risk approach was used for breast cancer–specific survival (BCSS). Standardized survival probabilities and cumulative incidence functions for breast cancer death were calculated for each treatment by age. Results Among 101 654 women, 72.2% received BCS + RT and 27.8% received mastectomy. Age, co-morbidity and frailty were associated with overall survival (OS), but only age and co-morbidity were associated with BCSS. Survival probabilities for OS were greater for BCS + RT (90.3%) versus mastectomy (87.0%), and the difference between treatments varied by age (50 years: 1.9% versus 80 years: 6.5%). Cumulative incidence functions for breast cancer death were higher after mastectomy (5.1%) versus BCS + RT (3.9%), but there was little change in the difference by age (50 years: 0.9% versus 80 years: 1.2%). The results highlight the change in baseline mortality risk by age for OS compared to the stable baseline for BCSS. Conclusion For OS, the difference in survival probabilities for BCS + RT and mastectomy increased slightly with age. The difference in cumulative incidence functions for breast cancer death by surgery type was small regardless of age. Evidence on real-world survival outcomes among older populations with breast cancer is informative for treatment decision-making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: protocol for a prospective, multicentre cohort study

Author

Hartup, Sue M., primary, Morgan, Jenna L., additional, Cheng, Vinton WT, additional, Barry, Peter A., additional, Copson, Ellen, additional, Cutress, Ramsey I., additional, Dave, Rajiv, additional, Elsberger, Beatrix, additional, Fairbrother, Patricia, additional, Hogan, Brian, additional, Horgan, Kieran, additional, Kirwan, Cliona C., additional, McIntosh, Stuart A., additional, O’Connell, Rachel L., additional, Patani, Neill, additional, Potter, Shelley, additional, Rattay, Tim, additional, Sheehan, Lisa, additional, Wyld, Lynda, additional, and Kim, Baek, additional

Published
2024
Full Text
View/download PDF

15. Observational cohort study to determine the degree and causes of variation in the rate of surgery or primary endocrine therapy in older women with operable breast cancer

Author

Lifford, Kate, Edwards, Adrian, Brain, Kate, Ring, Alistair, Robinson, Thomson, Chater, Tim, Pemberton, Kirsty, Shrestha, Anne, Nettleship, Anthony, Richards, Paul, Todd, Annaliza, Harder, Helena, Wright, Juliette, Simcock, Richard, Murray, Chris, Green, Tracy, Revill, Deirdre, Gath, Jacqui, Horgan, Kieran, Holcombe, Chris, Naik, Jay, Parmeshwar, Rishi, Morgan, Jenna L., Holmes, Geoff, Ward, Sue, Martin, Charlene, Burton, Maria, Walters, Stephen J., Cheung, Kwok Leung, Audisio, Riccardo A., Reed, Malcolm WR., and Wyld, Lynda

Published
2021
Full Text
View/download PDF

18. Breast malignancy

Author

Horgan, Kieran, additional, Dall, Barbara, additional, Millican-Slater, Rebecca, additional, Bramhall, Russell, additional, MacNeill, Fiona, additional, Dodwell, David, additional, Chaudhuri, Indu, additional, and Trainor, Sebastian, additional

Published
2021
Full Text
View/download PDF

19. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

Author

Smith, Ian, Robertson, John, Kilburn, Lucy, Wilcox, Maggie, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Kirwan, Cliona, Mallon, Elizabeth, Sibbering, Mark, Skene, Anthony, Vidya, Raghavan, Cheang, Maggie, Banerji, Jane, Morden, James, Sidhu, Kally, Dodson, Andrew, Bliss, Judith M, and Dowsett, Mitch

Published
2020
Full Text
View/download PDF

32. Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Author

Dave, Rajiv V., Kim, Baek, Courtney, Alona, O’Connell, Rachel, Rattay, Tim, Taxiarchi, Vicky P., Kirkham, Jamie J., Camacho, Elizabeth M., Fairbrother, Patricia, Sharma, Nisha, Cartlidge, Christopher W. J., Horgan, Kieran, McIntosh, Stuart A., Leff, Daniel R., Vidya, Raghavan, Potter, Shelley, Holcombe, Chris, Copson, Ellen, Coles, Charlotte E., Cutress, Ramsey I., Gandhi, Ashu, and Kirwan, Cliona C.

Published
2021
Full Text
View/download PDF

33. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Author

Dave, Rajiv, Elsberger, Beatrix, Taxiarchi, Paraskevi, Gandhi, Ashu, Kirwan, Cliona, Kim, Baek, Camacho, Liz, Coles, Charlotte, Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie, Leff, Daniel, McIntosh, Stuart, O’Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, and Cutress, Ramsey

Subjects
Breast cancer, SDG 3 - Good Health and Well-being, COVID-19, Neoadjuvant endocrine therapy, Bridging endocrine therapy
Abstract

Purpose: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources.Methods: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis.Results: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET.Discussion: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.

Published
2023

34. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Author

Dave, Rajiv V, Elsberger, Beatrix, Taxiarchi, Vicky P, Gandhi, Ashu, Kirwan, Cliona C, Kim, Baek, Camacho, Elizabeth M, Coles, Charlotte E, Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie J, Leff, Daniel R, McIntosh, Stuart A, O'Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, Cutress, Ramsey I, B-MaP-C Study Collaborative, Dave, Rajiv V [0000-0001-6827-8090], and Apollo - University of Cambridge Repository

Subjects
Cohort Studies, Ki-67 Antigen, Breast cancer, Humans, COVID-19, Female, Breast Neoplasms, Neoadjuvant endocrine therapy, Prognosis, Pandemics, Bridging endocrine therapy, Neoadjuvant Therapy
Abstract

PURPOSE: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources. METHODS: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis. RESULTS: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET. DISCUSSION: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.

Published
2023

35. Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., primary, Cheung, Kwok-Leung, primary, Evans, Abigail, primary, Holcombe, Chris, primary, Skene, Anthony, primary, Rea, Daniel, primary, Ahmed, Samreen, primary, Jahan, Ali, primary, Horgan, Kieran, primary, Rauchhaus, Petra, primary, Littleford, Roberta, primary, Cheung, S.Y. Amy, primary, Cullberg, Marie, primary, de Bruin, Elza C., primary, Koulai, Loumpiana, primary, Lindemann, Justin P.O., primary, Pass, Martin, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Deb, Rahul, primary, Finlay, Pauline, primary, Foxley, Andrew, primary, and Gee, Julia M.W., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Author

Bundred, Nigel, primary, Porta, Nuria, primary, Brunt, Adrian Murray, primary, Cramer, Angela, primary, Hanby, Andrew, primary, Shaaban, Abeer M., primary, Rakha, Emad A., primary, Armstrong, Anne, primary, Cutress, Ramsey I., primary, Dodwell, David, primary, Emson, Marie A., primary, Evans, Abigail, primary, Hartup, Sue M., primary, Horgan, Kieran, primary, Miller, Sarah E., primary, McIntosh, Stuart A., primary, Morden, James P., primary, Naik, Jay, primary, Narayanan, Sankaran, primary, Ooi, Jane, primary, Skene, Anthony I., primary, Cameron, David A., primary, and Bliss, Judith M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Author

Bundred, Nigel, primary, Porta, Nuria, primary, Brunt, Adrian Murray, primary, Cramer, Angela, primary, Hanby, Andrew, primary, Shaaban, Abeer M., primary, Rakha, Emad A., primary, Armstrong, Anne, primary, Cutress, Ramsey I., primary, Dodwell, David, primary, Emson, Marie A., primary, Evans, Abigail, primary, Hartup, Sue M., primary, Horgan, Kieran, primary, Miller, Sarah E., primary, McIntosh, Stuart A., primary, Morden, James P., primary, Naik, Jay, primary, Narayanan, Sankaran, primary, Ooi, Jane, primary, Skene, Anthony I., primary, Cameron, David A., primary, and Bliss, Judith M., primary

Published
2023
Full Text
View/download PDF

39. Additional file 3 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 3: Fig. S3. Log fold change in Ki67 A. for patients allocated control by sample. type, B. for patients allocated AI by sample type and choice of AI. Presented separately for HER2- and HER2- patients.

Published
2023
Full Text
View/download PDF

40. Additional file 1 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 1: Fig. S1. Distribution of Ki67Baseline a. Distribution of Ki67 % positive cells b. Distribution of ln(Ki67+0.1) c. Distribution of Ki67Baseline by HER2 status

Published
2023
Full Text
View/download PDF

41. Additional file 2 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 2: Fig. S2. Distribution of A. log(Ki67Baseline +0.1) for all patients, B. log(Ki672week +0.1) in patients allocated control, C. log fold. change Ki67 in patients allocated control, D. log(Ki672week +0.1) in patients allocated AI and E. log fold change Ki67 in patients allocated AI. Presented separately for HER2- and HER2+ patients.

Published
2023
Full Text
View/download PDF

42. Additional file 4 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 4: Table S1. Univariable and multivariable linear regression results for change in Ki67 in patients allocated to control by HER2 status. Table S2. Multivariable linear regression results for change in Ki67 in patients allocated to control by HER2 status showing adjustment for sample type. Table S3. Multivariable linear regression results for change in Ki67 in patients allocated to AI by HER2 status showing adjustment for sample type and AI choice. Table S4. CCCA by AI and sample type in patients allocated AI.

Published
2023
Full Text
View/download PDF

43. Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., additional, Cheung, Kwok-Leung, additional, Evans, Abigail, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Rea, Daniel, additional, Ahmed, Samreen, additional, Jahan, Ali, additional, Horgan, Kieran, additional, Rauchhaus, Petra, additional, Littleford, Roberta, additional, Amy Cheung, S.Y., additional, Cullberg, Marie, additional, de Bruin, Elza C., additional, Koulai, Loumpiana, additional, Lindemann, Justin P.O., additional, Pass, Martin, additional, Rugman, Paul, additional, Schiavon, Gaia, additional, Deb, Rahul, additional, Finlay, Pauline, additional, Foxley, Andrew, additional, and Gee, Julia M.W., additional

Published
2022
Full Text
View/download PDF

45. Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT

Author

Wyld, Lynda, primary, Reed, Malcolm WR, additional, Collins, Karen, additional, Ward, Sue, additional, Holmes, Geoff, additional, Morgan, Jenna, additional, Bradburn, Mike, additional, Walters, Stephen, additional, Burton, Maria, additional, Lifford, Kate, additional, Edwards, Adrian, additional, Brain, Kate, additional, Ring, Alistair, additional, Herbert, Esther, additional, Robinson, Thompson G, additional, Martin, Charlene, additional, Chater, Tim, additional, Pemberton, Kirsty, additional, Shrestha, Anne, additional, Nettleship, Anthony, additional, Richards, Paul, additional, Brennan, Alan, additional, Cheung, Kwok Leung, additional, Todd, Annaliza, additional, Harder, Helena, additional, Audisio, Riccardo, additional, Battisti, Nicolo Matteo Luca, additional, Wright, Juliet, additional, Simcock, Richard, additional, Murray, Christopher, additional, Thompson, Alastair M, additional, Gosney, Margot, additional, Hatton, Matthew, additional, Armitage, Fiona, additional, Patnick, Julietta, additional, Green, Tracy, additional, Revill, Deirdre, additional, Gath, Jacqui, additional, Horgan, Kieran, additional, Holcombe, Chris, additional, Winter, Matt, additional, Naik, Jay, additional, and Parmeshwar, Rishi, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results